Year: 2024
Type: article
Abstract: Abaloparatide stimulates osteoblast activity and is licensed for treating postmenopausal women with fracture risk. Here, we discuss the clinical evidence for benefit and also the drug adverse effect profile.
Source: Prescriber
DOI: 10.1002/psb.2160
Author: Steve Chaplin
Language: English
Subfield: Orthopedics and Sports Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4405450187